BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China · Delayed Price · Currency is CNY 32.94
+1.11 (3.49%)
At close: Jul 31, 2026
SHA:688166 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,300 | 1,224 | 1,283 | 1,180 | 1,017 | 1,052 |
Revenue Growth | 9.09% | -4.59% | 8.73% | 15.94% | -3.33% | 34.00% |
Gross Profit Gross Profit Growth | 683.29 | 608.23 | 722.04 | 636.61 | 626.38 | 582.34 |
Operating Income Operating Income Growth | 65.57 | 51.56 | 200.76 | 208.24 | 231.38 | 249.16 |
Net Income Net Income Growth | 50.85 | 54.51 | 189.17 | 202.47 | 239.62 | 243.95 |
Earnings Per Share EPS Growth | 0.12 | 0.13 | 0.45 | 0.48 | 0.58 | 0.60 |
EPS Growth | -63.68% | -71.11% | -6.25% | -17.24% | -3.33% | 46.34% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Income from sale of Products Income from sale of Products Growth | 1,079 | 1,149 | 1,023 | 877.52 | 927.8 |
Income from Technology Income from Technology Growth | 44.46 | 39.22 | 75.8 | 84.39 | 67.78 |
Equity Share Income Equity Share Income Growth | 66.07 | 60.04 | 61.9 | 51.39 | 54.58 |
Total Total Growth | 1,190 | 1,248 | 1,161 | 1,013 | 1,050 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,395 | 961.06 | 765.35 | 1,049 | 1,230 | 337.6 |
Total Debt Total Debt Growth | 3,089 | 2,395 | 2,236 | 2,207 | 2,022 | 902.42 |
Net Cash (Debt) Net Cash Growth | -1,694 | -1,433 | -1,470 | -1,158 | -791.15 | -564.82 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -3.96 | -3.42 | -3.50 | -2.75 | -1.91 | -1.39 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 106.93 | 325.19 | 245.56 | 194.77 | 311.26 | 176.08 |
Capital Expenditures CapEx Growth | -279.22 | -453.41 | -257.2 | -403.76 | -726.73 | -909.66 |
Free Cash Flow Free Cash Flow Growth | -172.29 | -128.22 | -11.64 | -209 | -415.47 | -733.59 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 52.58% | 49.71% | 56.30% | 53.97% | 61.57% | 55.33% |
Operating Margin | 5.04% | 4.21% | 15.65% | 17.66% | 22.74% | 23.67% |
Pretax Margin | 1.72% | 1.14% | 12.26% | 16.00% | 23.81% | 24.46% |
Profit Margin | 3.91% | 4.46% | 14.75% | 17.16% | 23.55% | 23.18% |
FCF Margin | -13.26% | -10.48% | -0.91% | -17.72% | -40.84% | -69.71% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.016 | 0.016 | 0.096 | 0.096 | 0.114 | 0.120 |
Dividend Per Share Growth | -83.33% | -83.33% | 0% | -15.79% | -5.00% | 42.86% |
Dividend Yield | 0.05% | 0.03% | 0.32% | 0.28% | 0.51% | 0.33% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 276.95 | 380.44 | 67.39 | 73.03 | 39.79 | 61.70 |
Forward PE | - | 82.45 | 52.98 | 28.00 | 28.00 | 43.06 |
PS Ratio | 11.03 | 16.95 | 9.94 | 12.54 | 9.37 | 14.30 |